Arotinolol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Arotinolol
Accession Number
DB09204
Type
Small Molecule
Groups
Approved
Description

Arotinolol is a medication in the class of mixed alpha/beta blockers.

Structure
Thumb
Synonyms
Not Available
External IDs
S-596
International/Other Brands
Almarl
Categories
UNII
394E3P3B99
CAS number
68377-92-4
Weight
Average: 371.53
Monoisotopic: 371.07959045
Chemical Formula
C15H21N3O2S3
InChI Key
BHIAIPWSVYSKJS-UHFFFAOYSA-N
InChI
InChI=1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20)
IUPAC Name
5-(2-{[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl}-1,3-thiazol-4-yl)thiophene-2-carboxamide
SMILES
CC(C)(C)NCC(O)CSC1=NC(=CS1)C1=CC=C(S1)C(N)=O

Pharmacology

Indication

Used in the treatment of high blood pressure.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Arotinolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Experimental, Illicit
AcebutololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Arotinolol.Approved
AcemetacinAcemetacin may decrease the antihypertensive activities of Arotinolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Arotinolol.Approved
AcetohexamideArotinolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Acetylcholine.Approved
AcetyldigitoxinArotinolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinArotinolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Arotinolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Experimental, Investigational
AlaproclateThe serum concentration of Arotinolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Arotinolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Aldesleukin.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Arotinolol.Approved, Illicit
AlfuzosinArotinolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Arotinolol is combined with Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Arotinolol.Experimental
AmbenoniumAmbenonium may increase the bradycardic activities of Arotinolol.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Arotinolol.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Amiloride.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Arotinolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Amlodipine.Approved
AmobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Arotinolol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Arotinolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Arotinolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Arotinolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Arotinolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Arotinolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Arotinolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Arecoline.Experimental
AripiprazoleAripiprazole may increase the hypotensive activities of Arotinolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Atenolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Arotinolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Arotinolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Arotinolol.Experimental
BarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Benazepril.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Arotinolol.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bendroflumethiazide.Approved
BenorilateBenorilate may decrease the antihypertensive activities of Arotinolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Arotinolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Illicit
BepridilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Arotinolol.Experimental
BisoprololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Arotinolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Arotinolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Arotinolol.Investigational
BucindololArotinolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Arotinolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Arotinolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bumetanide.Approved
BunazosinArotinolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Arotinolol.Approved, Investigational
CabergolineArotinolol may increase the vasoconstricting activities of Cabergoline.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Candesartan.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Arotinolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Arotinolol.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Carbetocin.Approved
CarbutamideArotinolol may increase the hypoglycemic activities of Carbutamide.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Carteolol.Approved
CarvedilolArotinolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Arotinolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Arotinolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Arotinolol.Experimental
ChlorpromazineChlorpromazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
ChlorpropamideArotinolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Chlorthalidone.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Arotinolol.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Arotinolol.Approved
ClozapineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Arotinolol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Arotinolol.Investigational
CymarinArotinolol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Arotinolol.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Arotinolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Arotinolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Arotinolol.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Desflurane.Approved
DeslanosideArotinolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Arotinolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Arotinolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Diclofenamide.Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Arotinolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Arotinolol.Approved
DigitoxinArotinolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinArotinolol may increase the bradycardic activities of Digoxin.Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Arotinolol is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Arotinolol is combined with Dinutuximab.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Arotinolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Arotinolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Arotinolol.Experimental
DonepezilDonepezil may increase the bradycardic activities of Arotinolol.Approved
DoxazosinArotinolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Arotinolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Arotinolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
DuloxetineArotinolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Arotinolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Arotinolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Arotinolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Arotinolol.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Arotinolol is combined with Enalaprilat.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Arotinolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Arotinolol is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Eprosartan.Approved
Ergoloid mesylateArotinolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineArotinolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
EsmololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Arotinolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Arotinolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Arotinolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Arotinolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
EtoperidoneThe serum concentration of Arotinolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Arotinolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Arotinolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Arotinolol.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Arotinolol.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Arotinolol.Approved
FentanylFentanyl may increase the bradycardic activities of Arotinolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Arotinolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Arotinolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Arotinolol.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Arotinolol.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fimasartan.Approved
FingolimodArotinolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Arotinolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Arotinolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Arotinolol.Experimental
FluoxetineThe serum concentration of Arotinolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Arotinolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Furosemide.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Arotinolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Arotinolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Arotinolol.Approved, Nutraceutical
GitoformateArotinolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideArotinolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideArotinolol may increase the hypoglycemic activities of Gliclazide.Approved
GlipizideArotinolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneArotinolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideArotinolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideArotinolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Arotinolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Arotinolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Halothane.Approved, Vet Approved
HexobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Arotinolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Arotinolol.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Hydroflumethiazide.Approved
HydroxychloroquineThe metabolism of Arotinolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Arotinolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Arotinolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Arotinolol.Approved
IloprostThe risk or severity of adverse effects can be increased when Arotinolol is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Arotinolol.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Imipramine.Approved
IndalpineThe serum concentration of Arotinolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Indapamide.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Arotinolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Arotinolol.Withdrawn
IndoraminArotinolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkArotinolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Arotinolol.Experimental
IrbesartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Arotinolol.Approved, Withdrawn
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Arotinolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isradipine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Arotinolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Arotinolol.Approved
LabetalolArotinolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Lacidipine.Approved
Lanatoside CArotinolol may increase the bradycardic activities of Lanatoside C.Experimental
LeflunomideLeflunomide may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Levobupivacaine.Approved
LevodopaArotinolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Arotinolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Levosimendan.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Arotinolol.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Arotinolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Arotinolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Arotinolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Arotinolol.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Arotinolol.Approved
MalathionMalathion may increase the bradycardic activities of Arotinolol.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Arotinolol is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Arotinolol.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Arotinolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Arotinolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Arotinolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Arotinolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Arotinolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Arotinolol.Approved
MetahexamideArotinolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Arotinolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Arotinolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Methazolamide.Approved
MethohexitalThe serum concentration of Arotinolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Arotinolol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Methyclothiazide.Approved
Methyl salicylateMethyl salicylate may increase the bradycardic activities of Arotinolol.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Arotinolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Arotinolol.Investigational
MethylergometrineArotinolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinArotinolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Arotinolol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Metoprolol.Approved, Investigational
MidodrineArotinolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Arotinolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Arotinolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Minoxidil.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Arotinolol.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Moexipril.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Arotinolol.Experimental
MoricizineMoricizine may increase the hypotensive activities of Arotinolol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Morphine.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Arotinolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Arotinolol.Approved
NadololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Arotinolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Arotinolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Arotinolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Arotinolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Arotinolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Arotinolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Arotinolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Arotinolol.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Arotinolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Arotinolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitroprusside.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Arotinolol is combined with Obinutuzumab.Approved
OleandrinArotinolol may increase the bradycardic activities of Oleandrin.Experimental
OlmesartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Olmesartan.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Arotinolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Arotinolol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Arotinolol.Vet Approved
OuabainArotinolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Arotinolol.Approved
OxprenololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Arotinolol.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Arotinolol is combined with Paclitaxel.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
PapaverineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Papaverine.Approved
ParaoxonParaoxon may increase the bradycardic activities of Arotinolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Arotinolol.Approved
ParoxetineThe serum concentration of Arotinolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Arotinolol.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Penbutolol.Approved, Investigational
PentobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Arotinolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Arotinolol.Approved
PeruvosideArotinolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Phenelzine.Approved
PhenobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Arotinolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pipamperone.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Arotinolol.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Arotinolol.Experimental
PramipexoleThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pramipexole.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Arotinolol.Experimental
PrazosinArotinolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Arotinolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Arotinolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Arotinolol.Experimental
PromazinePromazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Arotinolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Arotinolol.Approved
PropafenoneThe serum concentration of Arotinolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Arotinolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Arotinolol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Arotinolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Arotinolol.Experimental
ProscillaridinArotinolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Arotinolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Arotinolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Rasagiline.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Arotinolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Remifentanil.Approved
ReserpineReserpine may increase the hypotensive activities of Arotinolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Arotinolol.Experimental, Investigational
RifampicinThe serum concentration of Arotinolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Arotinolol can be decreased when it is combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Arotinolol is combined with Riociguat.Approved
RisperidoneArotinolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Arotinolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Arotinolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sacubitril.Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Arotinolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Arotinolol.Approved
SecobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Selegiline.Approved, Investigational, Vet Approved
SemapimodSemapimod may decrease the antihypertensive activities of Arotinolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Arotinolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Arotinolol.Investigational
SertralineThe serum concentration of Arotinolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sevoflurane.Approved, Vet Approved
SilodosinArotinolol may increase the orthostatic hypotensive activities of Silodosin.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Arotinolol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Arotinolol is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Arotinolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Arotinolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Arotinolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Arotinolol.Experimental
TacrineTacrine may increase the bradycardic activities of Arotinolol.Withdrawn
TamsulosinArotinolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Arotinolol.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Telmisartan.Approved, Investigational
TenidapTenidap may decrease the antihypertensive activities of Arotinolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Arotinolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Arotinolol.Vet Approved
TerazosinArotinolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Arotinolol.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe serum concentration of Arotinolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Arotinolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Arotinolol.Withdrawn
ThiopentalThe serum concentration of Arotinolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Arotinolol.Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Arotinolol.Approved
TimololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Timolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Arotinolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
TolazamideArotinolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Arotinolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Arotinolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Triamterene.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Arotinolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Arotinolol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Arotinolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
TrimazosinArotinolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TriptolideTriptolide may decrease the antihypertensive activities of Arotinolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Arotinolol.Approved
UrapidilArotinolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Arotinolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Valsartan.Approved, Investigational
VareniclineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Arotinolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Verapamil.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Arotinolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Arotinolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Arotinolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Arotinolol.Withdrawn
Food Interactions
Not Available

References

General References
  1. Zhao J, Golozoubova V, Cannon B, Nedergaard J: Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes. Can J Physiol Pharmacol. 2001 Jul;79(7):585-93. [PubMed:11478592]
  2. Lee KS, Kim JS, Kim JW, Lee WY, Jeon BS, Kim D: A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor. Parkinsonism Relat Disord. 2003 Aug;9(6):341-7. [PubMed:12853233]
  3. Wu H, Zhang Y, Huang J, Zhang Y, Liu G, Sun N, Yu Z, Zhou Y: Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers. Hypertens Res. 2001 Sep;24(5):605-10. [PubMed:11675958]
External Links
KEGG Drug
D07465
PubChem Compound
2239
PubChem Substance
310265112
ChemSpider
2152
BindingDB
81885
ChEBI
135569
ChEMBL
CHEMBL93298
Wikipedia
Arotinolol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD)1
4RecruitingTreatmentHypertension,Essential1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0225 mg/mLALOGPS
logP2.38ALOGPS
logP2.54ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)13.51ChemAxon
pKa (Strongest Basic)9.84ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area88.24 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity96.71 m3·mol-1ChemAxon
Polarizability40.66 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as thiophene carboxamides. These are compounds containing a thiophene ring which bears a carboxamide.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiophenes
Sub Class
Thiophene carboxylic acids and derivatives
Direct Parent
Thiophene carboxamides
Alternative Parents
2-heteroaryl carboxamides / Alkylarylthioethers / 2,5-disubstituted thiophenes / 2,4-disubstituted thiazoles / Heteroaromatic compounds / Secondary alcohols / Primary carboxylic acid amides / Amino acids and derivatives / 1,2-aminoalcohols / Sulfenyl compounds
show 5 more
Substituents
2-heteroaryl carboxamide / Aryl thioether / Thiophene carboxamide / 2,4-disubstituted 1,3-thiazole / Alkylarylthioether / 2,5-disubstituted thiophene / Azole / Heteroaromatic compound / Thiazole / 1,2-aminoalcohol
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 19, 2015 13:52 / Updated on October 02, 2017 06:14